viewCynata Therapeutics Ltd

Proactive Biotech Webinar attracts strong response

Presenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:PXS).

Cynata Therapeutics Ltd - Proactive Biotech Webinar attracts strong response
The biotech sector is attracting strong global interest.

The COVID-19 pandemic has placed more focus on biotech companies owing to the worldwide quest for a vaccine along with the need for increased personal hygiene.

While this research and development work has thrown a strong spotlight on those companies actively involved, other biotech companies seeking new solutions to medical issues are also reporting strong interest.

This interest also extended to today’s Proactive Biotech Webinar which drew a strong online presence and extensive subsequent viewing of the session.

Three presenters

Presenting companies were Cynata Therapeutics Ltd (ASX:CYP), Recce Pharmaceuticals Ltd (ASX:RCE) and Pharmaxis Ltd (ASX:PXS).

Cynata’s managing director Dr Ross Macdonald highlighted the company's progress towards multiple clinical trials using its Cymerus™ mesenchymal stem cell (MSC) products.

Recce chief executive officer James Graham summarised the company’s pathway towards developing and commercialising a new class of Synthetic Anti-infectives.

Subsequent to the webinar Recce received encouraging preliminary results from an antiviral screening program at The Doherty Institute evaluating RECCE 327, a synthetic anti-infective, against SAR-CoV-2.

Pharmaxis chief executive officer Gary Phillips outlined the transformational US Food & Drug Administration (FDA) agency’s approval of its cystic fibrosis treatment Bronchitol® (mannitol).

Reaching this top biotech echelon is one that very few Australian companies have achieved with Phillips saying that it is a “transformational step”.

The presentations can be viewed on this link: https://www.youtube.com/watch?v=NAmX5wpUv0k&ab_channel=Proactive

The session starts with Cynata while the Recce presentation begins at around the 24-minute 20-second mark and the Pharmaxis presentation at the 43-minute 20-second point.

Quick facts: Cynata Therapeutics Ltd

Price: 0.635 AUD

Market: ASX
Market Cap: $90.98 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...


Cynata Therapeutics announces trial in critical COVID-19 patients using...

Cynata Therapeutics (ASX: CYP) COO Kilian Kelly joined Steve Darling from Proactive Vancouver with news the unique stem cell biotech company is beginning a trial in patients suffering from the effects of the coronavirus. Kelly telling Proactive how their technology works and why this...

on 15/5/20

2 min read